A Cancer Innovation Crisis? Misplaced Incentives Promote Marginal Benefits, JAMA Study Says
Executive Summary
A study of oncology approvals since 2002 concludes that only 42% represented a “clinically meaningful improvement” in therapy. High prices encourage a “me-too” mentality that directs R&D investment to marginal indications, the authors assert.
You may also be interested in...
Cancer Trials Should Show Minimum 20% Overall Survival Benefit, ASCO Suggests
American Society of Clinical Oncology draft recommendations provide benchmarks for Phase III oncology drug trials, including a minimum 20% improvement in overall survival, with a higher bar for certain diseases.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.